Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced dosing of the first patient in its Phase 2 trial evaluating rinvatercept in patients with Duchenne muscular dystrophy (DMD). The trial aims to assess safety, tolerability, and functional improvements in late-ambulatory and early non-ambulatory DMD patients, signaling progress…